US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

登録

ホーム
投資
株式
アメリカ
NYSE
Johnson and Johnson (JNJ)
Johnson and Johnson (JNJ) ニュース

JNJ

Johnson and Johnson (JNJ)

Johnson and Johnson

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NYSE:JNJ

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/07/31	10 : 06	Edgar (US Regulatory)	Form SC 13G - Statement of Beneficial Ownership by Certain Investors	NYSE:JNJ	Johnson and Johnson
2024/07/31	07 : 42	PR Newswire (US)	DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible	NYSE:JNJ	Johnson and Johnson
2024/07/30	19 : 00	IH Market News	Toyota Reports Another Global Production Decline, Delta Sues CrowdStrike, Meta Launches AI Studio for Custom Chatbots	NYSE:JNJ	Johnson and Johnson
2024/07/30	05 : 00	Business Wire	Johnson & Johnson to Participate in the 2024 Wells Fargo Healthcare Conference	NYSE:JNJ	Johnson and Johnson
2024/07/26	22 : 38	Business Wire	Courts, Congress Likely to Stand in Way of J&J’s Third Texas Two-Step Plan	NYSE:JNJ	Johnson and Johnson
2024/07/26	22 : 05	Business Wire	FINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation Plan	NYSE:JNJ	Johnson and Johnson
2024/07/26	19 : 07	IH Market News	Alphabet Unveils AlphaProof and AlphaGeometry 2; OpenAI Tests SearchGPT; Apple Loses Market Share in China	NYSE:JNJ	Johnson and Johnson
2024/07/26	05 : 02	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NYSE:JNJ	Johnson and Johnson
2024/07/24	05 : 00	Business Wire	Johnson & Johnson to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference	NYSE:JNJ	Johnson and Johnson
2024/07/23	00 : 59	Business Wire	Lawyers for Ovarian Cancer Victims Urge NO Vote on J&J’s Latest Bankruptcy Plan	NYSE:JNJ	Johnson and Johnson
2024/07/22	21 : 00	PR Newswire (US)	Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression	NYSE:JNJ	Johnson and Johnson
2024/07/17	21 : 14	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:JNJ	Johnson and Johnson
2024/07/17	19 : 30	IH Market News	Tech-Led Decline in U.S. Index Futures Pre-Market, Oil Prices Steady After U.S. Inventory Drop	NYSE:JNJ	Johnson and Johnson
2024/07/17	19 : 28	IH Market News	Spirit Airlines Cuts Revenue Forecast, J.B. Hunt Disappoints Analysts’ Estimates, and More Earnings Updates	NYSE:JNJ	Johnson and Johnson
2024/07/17	19 : 25	Business Wire	Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2024	NYSE:JNJ	Johnson and Johnson
2024/07/17	19 : 20	Business Wire	Johnson & Johnson reports Q2 2024 results	NYSE:JNJ	Johnson and Johnson
2024/07/11	20 : 30	Business Wire	Johnson & Johnson Strengthens Pipeline to Lead in Atopic Dermatitis With the Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26	NYSE:JNJ	Johnson and Johnson
2024/07/10	06 : 48	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:JNJ	Johnson and Johnson
2024/07/03	21 : 00	PR Newswire (Canada)	Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations	NYSE:JNJ	Johnson and Johnson
2024/07/03	21 : 00	PR Newswire (Canada)	Santé Canada autorise le traitement par RYBREVANT® (amivantamab) en association avec le carboplatine et le pemetrexed comme seul traitement de première intention ciblé approuvé pour les patients atteints d'un cancer du poumon non à petites cellules p	NYSE:JNJ	Johnson and Johnson
2024/07/02	20 : 30	PR Newswire (US)	CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study	NYSE:JNJ	Johnson and Johnson
2024/06/29	00 : 30	PR Newswire (US)	Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients	NYSE:JNJ	Johnson and Johnson
2024/06/28	07 : 46	Business Wire	Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in Purdue	NYSE:JNJ	Johnson and Johnson
2024/06/21	20 : 30	Business Wire	Johnson & Johnson Completes Acquisition of Proteologix, Inc.	NYSE:JNJ	Johnson and Johnson
2024/06/21	05 : 30	PR Newswire (US)	Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease	NYSE:JNJ	Johnson and Johnson
2024/06/21	02 : 07	Business Wire	More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme	NYSE:JNJ	Johnson and Johnson
2024/06/20	21 : 00	PR Newswire (US)	TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction	NYSE:JNJ	Johnson and Johnson
2024/06/20	19 : 55	IH Market News	Trump Media Resells Stocks and Warrants; KB Home Exceeds Q2 Expectations, and More News	NYSE:JNJ	Johnson and Johnson
2024/06/18	06 : 55	Business Wire	Beasley Allen and Levin Papantonio: Leading Law Firms Seek Protection for Future Victims of Johnson & Johnson Talc Products	NYSE:JNJ	Johnson and Johnson
2024/06/17	21 : 00	PR Newswire (US)	Subcutaneous amivantamab Biologics License Application submitted to U.S. FDA for patients with EGFR-mutated non-small cell lung cancer	NYSE:JNJ	Johnson and Johnson

Showing the most relevant articles for your search:NYSE:JNJ

1 2 3 4 5 6 7 8 9 10 次へ >>

Gold vs US Dollar

BNP Paribas (QX)

Energy Select Sector SPDR

JP Morgan Chase

American Express

Deutsche Telekom (QX)

Health Care Select Sector

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約